Want to see IN:SUPRIYA full AI Analyst Report?

Supriya Lifescience Limited (SUPRIYA) Price & Analysis

0 Followers

SUPRIYA Stock Chart & Stats

₹751.00

-₹18.10(-2.41%)

At close: Jan 08 4:00 PM EST

₹751.00

-₹18.10(-2.41%)

Day’s Range― - ―

52-Week Range₹545.65 - ₹1,085.50

Previous CloseN/A

Volume168.68K

Average Volume (3M)18.01K

Market Cap

₹69.75B

Enterprise Value₹57.66K

Total Cash (Recent Filing)₹788.67M

Total Debt (Recent Filing)₹54.35M

Price to Earnings (P/E)33.4

Beta1.21

Next Earnings

Aug 10, 2026

EPS Estimate

9.3

Next Dividend Ex-DateN/A

Dividend Yield0.12%

Share Statistics

EPS (TTM)25.98

Shares Outstanding80,482,800

10 Day Avg. Volume18,341

30 Day Avg. Volume18,009

Financial Highlights & Ratios

PEG Ratio1.92

Price to Book (P/B)3.78

Price to Sales (P/S)5.46

P/FCF Ratio105.21

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)30.5

Revenue Forecast (FY)₹9.94B

Bulls Say, Bears Say

Bulls Say

Conservative Balance Sheet (low Leverage)A very low debt-to-equity position provides durable financial flexibility, lowers solvency risk, and supports continued capital spending or opportunistic M&A without pressuring cash flow. Over 2–6 months this reduces refinancing risk and preserves investment optionality as the company scales.

Consistent Revenue GrowthSustained, double-digit top-line expansion reflects growing demand for the company's APIs and successful market penetration. Durable revenue growth supports economies of scale, potential margin improvement over time, and funds reinvestment for capacity or product development across therapeutic areas.

Improving Operating Cash FlowA recent, sustained uplift in operating cash flow strengthens internal funding for capex, working capital, and R&D without raising leverage. Over the medium term this enhances earnings quality, reduces dependence on external finance, and supports disciplined investment in manufacturing capability.

Bears Say

Volatile Free Cash Flow HistoryHistorically uneven free cash flow signals that investments, working-capital swings or cyclical demand materially affect liquidity. Even with a recent rebound, past volatility implies potential variability in funding for dividends, buybacks, or discretionary growth spending absent sustained cash generation.

Margins And Earnings VolatilityFluctuating margins and earnings reduce predictability of long-term returns and complicate planning for capacity or R&D. Structural shifts in product mix, raw-material costs or contract pricing could keep earnings inconsistent across quarters, raising execution risk as the business grows.

Moderating Returns On EquityAs the company scales, ROE normalization suggests diminishing incremental returns on new investments. This structural moderation can pressure long-term profitability expectations unless productivity, pricing power, or higher-value product mix offsets dilution from a larger equity base.

Supriya Lifescience Limited News

Supriya Lifescience Seeks Shareholder Nod to Reappoint Whole Time Director via E-Voting

Supriya Lifescience Limited ( ($IN:SUPRIYA) ) has issued an announcement. Supriya Lifescience Limited has initiated a postal ballot...

13d ago

Supriya Lifescience Confirms SEBI Compliance on Dematerialised Securities

Supriya Lifescience Limited ( ($IN:SUPRIYA) ) has shared an announcement. Supriya Lifescience Limited has reported that its registrar...

25d ago

Supriya Lifescience Reports Customs Probe Into Senior Sales Executive

Supriya Lifescience Limited ( ($IN:SUPRIYA) ) has shared an update. Supriya Lifescience has disclosed that its General Manager...

1M ago

Supriya Lifescience Publishes Postal Ballot Notice in Newspapers

Supriya Lifescience Limited ( ($IN:SUPRIYA) ) has provided an update. Supriya Lifescience Limited notified the stock exchanges that...

5M ago

Supriya Lifescience Closes Trading Window Ahead of Q3 FY26 Results

An announcement from Supriya Lifescience Limited ( ($IN:SUPRIYA) ) is now available. Supriya Lifescience Limited has announced the...

7M ago

Supriya Lifescience Schedules Earnings Call to Discuss Financial Performance

Supriya Lifescience Limited ( ($IN:SUPRIYA) ) has issued an announcement. Supriya Lifescience Limited has announced an upcoming earnings...

9M ago

SUPRIYA FAQ

What was Supriya Lifescience Limited’s price range in the past 12 months?

Supriya Lifescience Limited lowest stock price was ₹545.65 and its highest was ₹1085.50 in the past 12 months.

What is Supriya Lifescience Limited’s market cap?

Supriya Lifescience Limited’s market cap is ₹69.75B.

When is Supriya Lifescience Limited’s upcoming earnings report date?

Supriya Lifescience Limited’s upcoming earnings report date is Aug 10, 2026 which is in 7 days.

How were Supriya Lifescience Limited’s earnings last quarter?

Supriya Lifescience Limited released its earnings results on May 27, 2026. The company reported ₹9.2 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.

Is Supriya Lifescience Limited overvalued?

According to Wall Street analysts Supriya Lifescience Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Supriya Lifescience Limited pay dividends?

Supriya Lifescience Limited pays a Annually dividend of ₹1 which represents an annual dividend yield of 0.12%. See more information on Supriya Lifescience Limited dividends here

What is Supriya Lifescience Limited’s EPS estimate?

Supriya Lifescience Limited’s EPS estimate is 9.3.

How many shares outstanding does Supriya Lifescience Limited have?

Supriya Lifescience Limited has 80,482,800 shares outstanding.

What happened to Supriya Lifescience Limited’s price movement after its last earnings report?

Supriya Lifescience Limited reported an EPS of ₹9.2 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.5%.

Which hedge fund is a major shareholder of Supriya Lifescience Limited?

Currently, no hedge funds are holding shares in IN:SUPRIYA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Supriya Lifescience Limited

Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. The company offers active pharmaceuticals ingredients in antihistamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, anti–hypertensive, vitamins, anti-malarial, and anti-gout areas. It also provides oncology, veterinary, and general category products. In addition, the company offers GelHeal, a wound care solution; and Quickblue, an oral cancer detection kit. Further, it is developing drugs in the areas of anti-depressant, anti-inflammatory, contrast media, hormones, antibiotic, smoking cessation, anti-diabetic/obesity, anti-ataxia, decongestant, veterinary API, anti-cancer, allogeneic hematopoietic stem cell transplantation, and anti-migraine. Supriya Lifescience Limited was founded in 1987 and is headquartered in Mumbai, India.